SCHEMBL20239255

SCHEMBL20239255

Nc1nc(CNc2ncc(Cl)cn2)cc(Oc2ccc(CCNS(N)(=O)=O)cc2)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT2 Q96PD7 1/20 0.53
RAB9A P51151 2/20 0.44
ALDH1A1 P00352 1/20 0.44
CA1 P00915 7/20 0.41
CA2 P00918 7/20 0.41
CA9 Q16790 7/20 0.41
CA12 O43570 4/20 0.41
CA14 Q9ULX7 3/20 0.41
CA5A P35218 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
CYP3A4 P08684 1/20 0.37
NPC1 O15118 1/20 0.35
MRGPRX1 Q96LB2 1/20 0.34
HDAC3 O15379 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
OPRM1 P35372 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20239226 0.93 DGAT2 (0.53) DGAT2RAB9AALDH1A1CA1CA2
SCHEMBL20239307 0.90 DGAT2 (0.55) DGAT2RAB9AALDH1A1CA1CA2
SCHEMBL20259121 0.90 SMN1; SMN2 (0.45) DGAT2RAB9AALDH1A1CA1CA2
SCHEMBL20239305 0.87 DGAT2 (0.49) DGAT2CA1CA2CA9CA12
SCHEMBL20239204 0.86 DGAT2 (0.69) DGAT2RAB9AALDH1A1CA1CA2
SCHEMBL20239216 0.85 DGAT2 (0.50) DGAT2RAB9AALDH1A1SMN1; SMN2MEN1
SCHEMBL20239165 0.85 DGAT2 (0.47) DGAT2RAB9AALDH1A1SMN1; SMN2MEN1
SCHEMBL20239177 0.84 DGAT2 (0.49) DGAT2RAB9AALDH1A1SMN1; SMN2MEN1
SCHEMBL20239222 0.83 SMN1; SMN2 (0.46) DGAT2RAB9AALDH1A1CA1CA2
SCHEMBL20239203 0.82 DGAT2 (0.59) DGAT2RAB9AALDH1A1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107635975-B DGAT2 inhibitors 伊莱利利公司 2020-07-24 CN disclosed
EP-3298001-B1 DGAT2 INHIBITORS LILLY CO ELI (US) 2020-05-13 EP disclosed
US-10053429-B2 DGAT2 inhibitors ELI LILLY AND COMPANY (US) 2018-08-21 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162825-A1 NOVEL DGAT2 INHIBITORS DGAT2, DGAT1, LCAT DGAT2 1/4885RAB9A 1170/4885ALDH1A1 1430/4885
US-10053429-B2 DGAT2 inhibitors DGAT2, DGAT1, LCAT DGAT2 1/4885RAB9A 1119/4885ALDH1A1 1189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.